Comparative Pharmacology
Head-to-head clinical analysis: ASCLERA versus LETAIRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASCLERA versus LETAIRIS.
ASCLERA vs LETAIRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASCLERA (corticotropin) is a proopiomelanocortin (POMC) analog that stimulates the adrenal cortex to release cortisol, corticosterone, and aldosterone, increasing corticosteroid levels. It also has immunomodulatory and anti-inflammatory effects mediated through melanocortin receptors.
Ambrisentan is an endothelin receptor antagonist that selectively inhibits endothelin-1 (ET-1) binding to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle cells, reducing vasoconstriction and smooth muscle proliferation.
Adults: 240 mg/m2 intravenously over 2 hours on day 1 of each 21-day cycle.
5 mg orally once daily, with or without food; may increase to 10 mg once daily if tolerated.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. In patients with moderate-to-severe renal impairment (CrCl < 30 mL/min), half-life may increase to 30-40 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 9 hours (range 6–12 hours) in healthy adults.
Renal excretion of unchanged drug accounts for 60-70% of administered dose; fecal/biliary elimination contributes 20-30%.
Primarily via biliary/fecal elimination (approximately 80% of metabolites and unchanged drug; ~20% renal as metabolites).
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist